Senior director at a European biopharmaceutical
- Core bioanalysis services, rate of outsourcing and shifting lab requirements in context of wider biopharma and diagnostic market developments, including specialised talent acquisition headwind and shift to new modalities – bispecifics, oligonucleotides and C>s (cell and gene therapies)
- Customer KPC (key purchase criteria), significance of a one-stop-shop offering vs specialisation and contract economics
- Bioanalytical CRO (contract research organisation) competitive landscape and segmentation across tier 1 and 2 players
- BioAgilytix, KCAS Bioanalytical & Biomarker Services, CellCarta and Nexelis – sources of differentiation, competitive advantage and consolidation outlook
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.